These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33762108)

  • 21. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
    Lundberg P; Karow A; Nienhold R; Looser R; Hao-Shen H; Nissen I; Girsberger S; Lehmann T; Passweg J; Stern M; Beisel C; Kralovics R; Skoda RC
    Blood; 2014 Apr; 123(14):2220-8. PubMed ID: 24478400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
    Iurlo A; Cattaneo D; Gianelli U
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
    Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
    Front Immunol; 2020; 11():604142. PubMed ID: 33329600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
    Li B; Mascarenhas JO; Rampal RK
    Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
    Odenike O
    Blood; 2018 Nov; 132(22):2339-2350. PubMed ID: 30333119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
    Tallarico M; Odenike O
    Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of advanced phase myeloproliferative neoplasms.
    Marcellino B; Mascarenhas J
    Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
    Rampal R; Mascarenhas J
    Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.
    Sato S; Itonaga H; Taguchi M; Sawayama Y; Imanishi D; Tsushima H; Hata T; Moriuchi Y; Mishima H; Kinoshita A; Yoshiura KI; Miyazaki Y
    Int J Hematol; 2018 Aug; 108(2):213-217. PubMed ID: 29417354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
    Gupta V; Kim S; Hu ZH; Liu Y; Aljurf M; Bacher U; Beitinjaneh A; Cahn JY; Cerny J; Copelan E; Gadalla SM; Gale RP; Ganguly S; George B; Gerds AT; Gergis U; Hamilton BK; Hashmi S; Hildebrandt GC; Kamble RT; Kindwall-Keller T; Lazarus HM; Liesveld JL; Litzow M; Maziarz RT; Nishihori T; Olsson RF; Rizzieri D; Savani BN; Seo S; Solh M; Szer J; Verdonck LF; Wirk B; Woolfrey A; Yared JA; Alyea EP; Popat UR; Sobecks RM; Scott BL; Nakamura R; Saber W
    Blood Adv; 2020 Oct; 4(19):4748-4757. PubMed ID: 33007075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent insights regarding the molecular basis of myeloproliferative neoplasms.
    Jang MA; Choi CW
    Korean J Intern Med; 2020 Jan; 35(1):1-11. PubMed ID: 31778606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomics of MPN progression.
    Patel AA; Odenike O
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):440-449. PubMed ID: 33275731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
    Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.
    Zhou S; Tremblay D; Hoffman R; Kremyanskaya M; Najfeld V; Li L; Moshier E; Mascarenhas J
    Acta Haematol; 2021; 144(1):48-57. PubMed ID: 32160610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.
    Zuo Z; Li S; Xu J; You MJ; Khoury JD; Yin CC
    Curr Hematol Malig Rep; 2019 Oct; 14(5):376-385. PubMed ID: 31388824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.
    Maslah N; Benajiba L; Giraudier S; Kiladjian JJ; Cassinat B
    Leukemia; 2023 May; 37(5):957-963. PubMed ID: 37002477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.
    Mughal TI; Barbui T; Abdel-Wahab O; Kralovics R; Jamieson C; Kvasnicka HM; Mullaly A; Rampal R; Mesa R; Kiladjian JJ; Deininger M; Prchal J; Hehlmann R; Saglio G; Van Etten RA
    Leuk Lymphoma; 2015 Jul; 56(7):1938-48. PubMed ID: 25330439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy.
    Zhao Y; Siddiqi I; Wildes TJ; Charles D; Deak K; Wang E
    Arch Pathol Lab Med; 2024 Dec; 148(12):1310-1319. PubMed ID: 38426696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.